Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Glargine-300 could be preferable for older individuals with kind 2 diabetes
medwireNews: The analysis of older participants in the BRIGHT study suggests that...
Important Oil Market In Depth Perception, Business Alternatives And Funding Overview Development & Analysis...
Scope of Trending Essential Oils Market report
(April 2021) Polaris Market Research recently did a research report on the Essential Oils Market covers an in-depth...